304 related articles for article (PubMed ID: 22894140)
1. Scenario drafting to anticipate future developments in technology assessment.
Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
[TBL] [Abstract][Full Text] [Related]
2. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
4. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.
Retèl VP; Bueno-de-Mesquita JM; Hummel MJ; van de Vijver MJ; Douma KF; Karsenberg K; van Dam FS; van Krimpen C; Bellot FE; Roumen RM; Linn SC; van Harten WH
Int J Technol Assess Health Care; 2009 Jan; 25(1):73-83. PubMed ID: 19126254
[TBL] [Abstract][Full Text] [Related]
5. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
[TBL] [Abstract][Full Text] [Related]
6. Value of research and value of development in early assessments of new medical technologies.
Retèl VP; Grutters JP; van Harten WH; Joore MA
Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
[TBL] [Abstract][Full Text] [Related]
8. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
9. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
11. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
Lindenberg M; Retèl V; Rohaan M; van den Berg J; Haanen J; van Harten W
BMC Cancer; 2020 Jul; 20(1):712. PubMed ID: 32736535
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.
Retèl VP; Joore MA; van Harten WH
Breast Cancer Res Treat; 2012 Jan; 131(2):627-36. PubMed ID: 21947677
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Hall PS; McCabe C; Stein RC; Cameron D
J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
[TBL] [Abstract][Full Text] [Related]
14. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
15. Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
Retèl VP; Joore MA; Drukker CA; Bueno-de-Mesquita JM; Knauer M; van Tinteren H; Linn SC; van Harten WH
Eur J Cancer; 2013 Dec; 49(18):3773-9. PubMed ID: 23992641
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
17. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
18. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
19. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY; Chen T; Dang W; Mougalian SS; Evans SB; Gross CP
J Natl Compr Canc Netw; 2019 Jan; 17(1):39-46. PubMed ID: 30659128
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]